PRESTIGE CONSUMER HEALTHCARE INC. Pre-Tax Income
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Pre-Tax Income of $257.50 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-14.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-05-14
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2020-03-31 was $50.53M.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2019-12-31 was $50.55M, a 0.87% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2019-09-30 was $44.01M, a 1.13% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2019-06-30 was $46.05M, a 0.88% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2026 was $257.50M, a 9.39% decline from fiscal 2025.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $284.19M, a 2.96% increase from fiscal 2024.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was $276.02M.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$93.92M, a 135.78% decline from fiscal 2022.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-03-31 | $257.50M 10-K · filed 2026-05-14 | |||
| 2025-03-31 | $284.19M 10-K · filed 2026-05-14 | |||
| 2024-03-31 | $276.02M 10-K · filed 2026-05-14 | |||
| 2023-03-31 | -$93.92M 10-K · filed 2025-05-09 | |||
| 2022-03-31 | $262.46M 10-K · filed 2024-05-15 | |||
| 2021-03-31 | $204.11M 10-K · filed 2023-05-05 | |||
| 2020-03-31 | $50.53M 10-K · filed 2020-05-08 | $101.09M derived: sum of 2 quarters · filed 2020-05-08 | $145.10M derived: sum of 3 quarters · filed 2020-05-08 | $191.15M 10-K · filed 2022-05-06 |
| 2019-12-31 | $50.55M 10-K · filed 2020-05-08 | $94.57M derived: sum of 2 quarters · filed 2020-05-08 | $140.62M derived: sum of 3 quarters · filed 2020-05-08 | -$38.41M derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-09-30 | $44.01M 10-K · filed 2020-05-08 | $90.06M derived: sum of 2 quarters · filed 2020-05-08 | -$88.97M derived: sum of 3 quarters · filed 2020-05-08 | -$37.97M derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-06-30 | $46.05M 10-K · filed 2020-05-08 | -$132.98M derived: sum of 2 quarters · filed 2020-05-08 | -$81.98M derived: sum of 3 quarters · filed 2020-05-08 | -$38.47M derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-03-31 | -$179.03M 10-K · filed 2020-05-08 | -$128.03M derived: sum of 2 quarters · filed 2020-05-08 | -$84.52M derived: sum of 3 quarters · filed 2020-05-08 | -$38.05M 10-K · filed 2021-05-07 |
| 2018-12-31 | $51.00M 10-K · filed 2020-05-08 | $94.52M derived: sum of 2 quarters · filed 2020-05-08 | $140.97M derived: sum of 3 quarters · filed 2020-05-08 | $88.41M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-09-30 | $43.52M 10-K · filed 2020-05-08 | $89.98M derived: sum of 2 quarters · filed 2020-05-08 | $37.42M derived: sum of 3 quarters · filed 2020-05-08 | $95.06M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-06-30 | $46.46M 10-K · filed 2020-05-08 | -$6.10M derived: sum of 2 quarters · filed 2020-05-08 | $51.54M derived: sum of 3 quarters · filed 2020-05-08 | $100.86M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-03-31 | -$52.56M 10-K · filed 2019-05-13 | $5.08M derived: sum of 2 quarters · filed 2019-05-13 | $54.40M derived: sum of 3 quarters · filed 2019-05-13 | $107.09M 10-K · filed 2020-05-08 |
| 2017-12-31 | $57.64M 10-K · filed 2019-05-13 | $106.96M derived: sum of 2 quarters · filed 2019-05-13 | $159.65M derived: sum of 3 quarters · filed 2019-05-13 | $178.45M derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-09-30 | $49.32M 10-K · filed 2019-05-13 | $102.01M derived: sum of 2 quarters · filed 2019-05-13 | $120.81M derived: sum of 3 quarters · filed 2019-05-13 | $171.54M derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-06-30 | $52.69M 10-K · filed 2019-05-13 | $71.49M derived: sum of 2 quarters · filed 2019-05-13 | $122.22M derived: sum of 3 quarters · filed 2019-05-13 | $172.45M derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-03-31 | $18.80M 10-K · filed 2018-05-10 | $69.53M derived: sum of 2 quarters · filed 2018-05-10 | $119.76M derived: sum of 3 quarters · filed 2018-05-10 | $110.85M 10-K · filed 2019-05-13 |
| 2016-12-31 | $50.73M 10-K · filed 2018-05-10 | $100.96M derived: sum of 2 quarters · filed 2018-05-10 | $92.05M 10-Q · filed 2017-02-02 | $116.65M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-09-30 | $50.23M 10-K · filed 2018-05-10 | $41.31M 10-Q · filed 2016-11-03 | $65.92M derived: sum of 3 quarters · filed 2018-05-10 | $109.10M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-06-30 | -$8.91M 10-K · filed 2018-05-10 | $15.69M derived: sum of 2 quarters · filed 2018-05-10 | $58.87M derived: sum of 3 quarters · filed 2018-05-10 | $108.10M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-03-31 | $24.60M 10-K · filed 2017-05-17 | $67.78M derived: sum of 2 quarters · filed 2017-05-17 | $117.02M derived: sum of 3 quarters · filed 2017-05-17 | $157.19M 10-K · filed 2018-05-10 |
| 2015-12-31 | $43.18M 10-K · filed 2017-05-17 | $92.41M derived: sum of 2 quarters · filed 2017-05-17 | $132.58M 10-Q · filed 2017-02-02 | $170.03M derived: sum of 4 quarters · filed 2017-05-17 |
| 2015-09-30 | $49.23M 10-K · filed 2017-05-17 | $89.40M 10-Q · filed 2016-11-03 | $126.85M derived: sum of 3 quarters · filed 2017-05-17 | $160.38M derived: sum of 4 quarters · filed 2017-05-17 |
| 2015-06-30 | $40.17M 10-K · filed 2017-05-17 | $77.62M derived: sum of 2 quarters · filed 2017-05-17 | $111.15M derived: sum of 3 quarters · filed 2017-05-17 | $139.48M derived: sum of 4 quarters · filed 2017-05-17 |
| 2015-03-31 | $37.45M 10-K · filed 2016-05-17 | $70.98M derived: sum of 2 quarters · filed 2016-05-17 | $99.31M derived: sum of 3 quarters · filed 2016-05-17 | $127.46M 10-K · filed 2017-05-17 |
| 2014-12-31 | $33.53M 10-K · filed 2016-05-17 | $61.86M derived: sum of 2 quarters · filed 2016-05-17 | $90.01M 10-Q · filed 2016-02-04 | $116.71M derived: sum of 4 quarters · filed 2016-05-17 |
| 2014-09-30 | $28.32M 10-K · filed 2016-05-17 | $56.48M 10-Q · filed 2015-11-05 | $83.18M derived: sum of 3 quarters · filed 2016-05-17 | $87.36M derived: sum of 4 quarters · filed 2016-05-17 |
| 2014-06-30 | $28.15M 10-K · filed 2016-05-17 | $54.85M derived: sum of 2 quarters · filed 2016-05-17 | $59.04M derived: sum of 3 quarters · filed 2016-05-17 | $96.36M derived: sum of 4 quarters · filed 2016-05-17 |
| 2014-03-31 | $26.70M 10-K · filed 2015-05-14 | $30.89M derived: sum of 2 quarters · filed 2015-05-14 | $68.21M derived: sum of 3 quarters · filed 2015-05-14 | $101.75M 10-K · filed 2016-05-17 |
| 2013-12-31 | $4.19M 10-K · filed 2015-05-14 | $41.51M derived: sum of 2 quarters · filed 2015-05-14 | $75.05M 10-Q · filed 2015-02-05 | $105.54M derived: sum of 4 quarters · filed 2015-05-14 |
| 2013-09-30 | $37.32M 10-K · filed 2015-05-14 | $70.86M 10-Q · filed 2014-11-06 | $101.35M derived: sum of 3 quarters · filed 2015-05-14 | $121.41M derived: sum of 4 quarters · filed 2015-05-14 |
| 2013-06-30 | $33.54M 10-K · filed 2015-05-14 | $64.03M derived: sum of 2 quarters · filed 2015-05-14 | $84.09M derived: sum of 3 quarters · filed 2015-05-14 | $115.58M derived: sum of 4 quarters · filed 2015-05-14 |
| 2013-03-31 | $30.49M 10-K · filed 2014-05-19 | $50.55M derived: sum of 2 quarters · filed 2014-05-19 | $82.05M derived: sum of 3 quarters · filed 2014-05-19 | $106.03M 10-K · filed 2015-05-14 |
| 2012-12-31 | $20.06M 10-K · filed 2014-05-19 | $51.56M derived: sum of 2 quarters · filed 2014-05-19 | $75.54M 10-Q · filed 2014-02-07 | $76.34M derived: sum of 4 quarters · filed 2014-05-19 |
| 2012-09-30 | $31.50M 10-K · filed 2014-05-19 | $55.48M 10-Q · filed 2013-11-07 | $56.28M derived: sum of 3 quarters · filed 2014-05-19 | $71.80M derived: sum of 4 quarters · filed 2014-05-19 |
| 2012-06-30 | $23.98M 10-K · filed 2014-05-19 | $24.79M derived: sum of 2 quarters · filed 2014-05-19 | $40.30M derived: sum of 3 quarters · filed 2014-05-19 | $61.42M derived: sum of 4 quarters · filed 2014-05-19 |
| 2012-03-31 | $800.00K 10-K · filed 2013-05-17 | $16.31M derived: sum of 2 quarters · filed 2013-05-17 | $37.44M derived: sum of 3 quarters · filed 2013-05-17 | $61.16M 10-K · filed 2014-05-19 |
| 2011-12-31 | $15.51M 10-K · filed 2013-05-17 | $36.64M derived: sum of 2 quarters · filed 2013-05-17 | $60.36M 10-Q · filed 2013-02-07 | |
| 2011-09-30 | $21.12M 10-K · filed 2013-05-17 | $44.84M 10-Q · filed 2012-11-07 | ||
| 2011-06-30 | $23.72M 10-K · filed 2013-05-17 | |||
| 2011-03-31 | $48.53M 10-K · filed 2013-05-17 | |||
| 2010-03-31 | $52.73M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |